Pregnant with migraines? study tracks medicine safety for mom and baby
NCT ID NCT05158894
Summary
This study aims to understand the safety of two migraine medicines, Ubrelvy and Qulipta, when taken during pregnancy. It will follow about 1,884 pregnant women with migraines in the US and Canada to track health outcomes for both mothers and their babies up to one year after birth. The goal is to gather information, not to test a new treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MIGRAINE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Iqvia /Id# 266904
RECRUITINGDurham, North Carolina, 27703-8426, United States
-
Ottawa Hospital Research Institute /ID# 280174
RECRUITINGOttawa, Ontario, K1Y 4E9, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.